cardiac anaesthesia and icm pocket book university hospital … · 2019. 6. 28. · e1 6470/3267 e2...
TRANSCRIPT
CardiacAnaesthesiaandICMPocketbook
UniversityHospitalSouthampton
Name………………………………………….
AssignmentNumber……………………
�
NGoddardandJHuber
June2019
---------� 2
TableofContents
---------� 3
Ch.1-Usefulcontacts 10............................CardiacTheatres 11.........................................
TheatresContacts: 11......................................
TheatreLists: 11..............................................
CatheterLabs: 12.............................................
Wards: 12........................................................
CICU: 13...........................................................
CICU-relatedusefulcontacts: 14.....................
CICUEmergencies: 16......................................
Anaesthe6cContacts: 17............................Consultants 17.................................................
Traineesandfellows 18...................................
Alliedstaff: 18..................................................
Hospitalusefulcontactinfo 20....................IT: 21..........................................................Scheduledmee6ngs: 22..............................Management: 23........................................UsefulCodes: 24.........................................
---------� 4
Ch.2–CardiacTheatres(Periopera6ve) 24.PreoperaVveAssessment: 25..........................
AnaestheVcRoom: 26.....................................
CPB: 34............................................................
ComingoffCPB: 36..........................................
‘Product’Types: 42..........................................
Ch.3-Echocardiography 43........................Intraopera6veTOEGuide: 43......................GeneralOverview: 45......................................
AVRProtocol(StructuralViews): 46................
AVRProtocol(ASdopplerviews):AVRProtocol(ARdopplerviews): 48......................
LVAssessment: 50...........................................
MitralvalveProtocol1(2DViews): 52............
MVProtocol2(RV+/-TVA): 54.......................
LAAO: 55..........................................................
OtherStructures: 56........................................
---------� 5
ProstheVcAorVcvalvesatUHS: 57.................
TOE:Mapofviews 60......................................
20StandardTOEviews 61...............................
Chamberandfunc6onquan6fica6on 63.....Lecatrialsize 63..............................................
LecVentricularsizeandfuncVon 64...............
AorVcStenosis(reference): 64........................
AorVcRegurgitaVon(reference): 65................
Rightventricularsizeandfunc6on 66.........LecventriculardiastolicfuncVon 68...............
Ch.4-Postopera6ve: 69.............................CardiacTransfusionProtocol 70......................
HaemofiltraVon: 71.........................................
LowCardiacOutputState: 74..........................
SupportforLowCO/ECMO: 75.......................
-Inotropes,IABP,ECMO 75.............................
-ECMOmaintenance(mainlyonCICU): 75.....
---------� 6
HCT40-45% 75................................................
Plts>80 75......................................................
ACT180-240 75...............................................
LowTVIPPV<5mL/Kg 75................................
1.Clamparterialline 75..................................
2.Clampvenousline 75..................................
3.stoppump 75...............................................
4.Runcystalloidintocircuit+drain/purge75
5.manipulatepumpheadtoencourageairtowardsoxygenator 75....................................
PulmonaryHTN: 76.........................................
Heparin-inducedthrombocytopenia 78..........
Ch.5–Congenitalinforma6on 81...............Aclassifica6onofcongenitallesions 81......1.‘Simple’lec-to-rightshunt(Qp>Qs),withincreasedpulmonarybloodflow 81................
2.‘Simple’right-to-lecshunt(Qp<Qs),withdecreasedpulmonarybloodflow&cyanosis.
---------� 7
82
3.‘Complex’shunts,withcomplexmixingofpulmonaryandsystemicblood,andthusacomplexinterplaybetweenpulmonary(Qp)andsystemic(Qs)bloodflow 82.....................
4.ObstrucVvelesions 83.................................
Qp:Qs 84....................................................FactorsincreasingPVR 87................................
FactorsdecreasingPVR 87...............................
APossiblecirculatorytroubleshooVngstrategypostNorwoodbasedonSvO2: 88.....
TroubleshooVngdifferenValdiagnosispostSCPA/Glenn 89.................................................
TroubleshooVngdifferenValdiagnosispostFontan 90.........................................................
Congenitalheartdisease–Anintroductoryglossaryofterms 91....................................Ch.6–Druginforma6on 98........................An6microbials: 98.......................................
---------� 8
Seda6vesandanxioly6cs: 106....................Shiveringassociatedwithhypothermia: 111..
Acid/basespecialsituaVons 112.....................
Cardiovasculardrugs: 113...........................Adrenaline: 113...............................................
Amiodarone: 115.............................................
AproVnin: 117..................................................
Atenolol 118....................................................
Atropine: 120...................................................
CalciumGluconate: 122...................................
Digoxin: 124.....................................................
Dopamine: 125................................................
Ephedrine: 128................................................
Esmolol: 130....................................................
GTN: 132..........................................................
Isoprenaline: 134.............................................
Levosimendan: 135.........................................
---------� 9
Ch. 1 - Useful contacts
Theatre/Catheter/WardAreas
Lidocaineinfusion: 137....................................
MethyleneBlue: 139.......................................
Milrinone: 141.................................................
Noradrenaline: 143..........................................
Phentolamine: 144..........................................
Phenylephrine: 146.........................................
SodiumNitroprusside(SNP): 148....................
Vasopressin: 150..............................................
Ch.7–Notes 151........................................
---------� 10
Cardiac Theatres TheatreA 1986 TheatreB 1987TheatreC 1988 Theatre3 3413Theatre4 8949 CoffeeRoom 4528TheatresOffice 4531
Theatres Contacts: CaseManagers bl2166 Office 5333/8686Coordinator bl9217 Office 4531O/CCTRegistrar bl9211 O/CCTSHO bl2311CTRegistraroffice 3674MainThCoord bl2894 Perfusion 6930PPMTechs bl9073 Office 3639ICUTechs bl2317 Office 6890Transfusion 4620 Theatre12 4073AnSupportODP bl9266 FLevRecov 4396TAs 07795306370/bl1489NB4 1062 AngioVRoom 4200[Send>08:00.Teambrief08:20]
TheatreLists: Casemanagersoffice(D-levelNorthwingadminoffices,EndofCICU,throughaccessdoor)daybeforeprovisional>approx1600.
---------� 11
Catheter Labs: CathLab1 4547/3459 Recep 4233CathLab2 4535/3126 CLDU 4420CathLab3 8206/3124 CLDUSR 3434CathLab4 4534/1081 Hybrid 5602CathLab5 3996 HybAR 5600
Lists->CLDU(Paper)or‘cardss’login->Gdrive->cathlabs->lists
Wards: CHDU(Med) 6835 CHDU(Sur) 6836CHDU(SR) 6903 CCU 8570/8572CLDU 4420 HFUnit 3140E1 6470/3267 E2 6473/3206E3G(Right) 6472 E3B(lec) 4111E4 6498/3206 D4 8468EDResus 4979 F10/SDU: 6471(RecepVon)Green 3809 Orange 3722Purple 3710 Yellow 348Blue 8066
WardTeamcontacts:ANP:bleep12315/bleep22330/Office8182/3872CTSHObl1511/OCbl2311,SpRbl2472,OCbl9211
---------� 12
CICU:
BlueSide: PinkSide:
Nursingstn 6122 5080
3574 4394
Office 4158 4273
WardClerk 6121 5923
CoffeeRoom 1240
Copier 6121/3245
BedSpaces:
Blue8 1889 Pink8 1895
Blue7 1890 Pink7 1899
Blue6 1896 Pink6 1900
---------� 13
Blue5 1897 Pink5 1901
Blue4 1891 Pink4 1838
Blue3 1892 Pink3 1869
Blue2 1893 Pink2 1904
Blue1 1894 Pink1 3688
Telephoneredirect *3
Staff:
Fellow bl1660 SPR bl2310
Cons bl2251 Sisteri/c bl1491
CICU-related useful contacts:
AcutePainTeam bl2974
CardiologySpR bl2390
ChestXR (Day/Northwing) 8347
---------� 14
ChestXR(OOH=A+E) 3294
CISTeambl1794/Office 4496CTHeadRequests 6588
CTScanner(BLevel) 3479
Echo(Requests) 6368
Endoscopy(TOEprobes) 4791
GeneralSurgerySpR bl9990
MainXR 4040
Microbiology 4203/6408/bl2216
NeuroSpR bl2580
NursepracVVoners 8182/bl9195
PacemakerTechs 3639/bl9073
Pharmacy 6313/bl2408
RadiologyRegistrarsRoom 3657
StrokeTeamSN bl1592
TechsICU(Trauma) 1874
---------� 15
TechsICU(Other) 9297
TraumaScannerRegistrarsSeat 8002
VascularDayBleepholder bl1322
CICU Emergencies:
1.Chestopening/returntotheatre:
-CardiacCoordinatorbl9217
-CardiacTheatresOffice4531
-PerfusionOffice6930
-Perfusionbl2322
-ODPSupportbl9266
-Transfusion4620
-TheatreCoordinatorbl2894
2.CrashCall–2222
---------� 16
Askfor“CardiacSurgicalTeam+CardiologyRegistrar”+locaVonCICU
3.Otherneedforoncallperfusionistoutofhours:
-NameslocatedonBluesideWhiteboard
-Numbers(+Cons/Regs)BluesideFlipcharts
Anaesthe?c Contacts: Emergencytheatresteam 2222
Consultants
CardiacCICUconsultant bl2251
MajTraumaAnaesConsultant bl1783
NamedAnaesConsultant bl1646
ObstetricAnaesDayConsultant bl2372
---------� 17
Trainees and fellows
AnaestheVcCoordinatorSpR bl2265
CICU(Anaes)SpR bl2310
CICUFellow bl1660
GICUSpR bl2110
NeuroAnaesSpR bl2510
ObstetricAnaesSpR bl2410
PaedsAnaesSpR bl2210
TraumaAnaesthesiaSpR/CEPODSHO
bl2050
Allied staff:
ODP(Anaessupport) bl9266
ODP(MajTrauma) bl1784
Theatrecoordinator bl2894
---------� 18
Anaesthe?c Admin Team
�Theadminoffice
……………………………………………………………………
DepartmentofAnaestheVcs
MP24,E-levelCentreBlock,
SGH,TremonaRoad,Soton.SO166YD.
Fax:02381204348Tel:206135/6720
---------� 19
Coffeeroom 3367
Switchboard 02380777222
SueDenton 8707
Hospital useful contact info
[email protected] RecepVon 02381206525
PayrollHelpdesk 03031231144
SylviaRichards(tradminmanager) 6741
Mon–Thurs9-5pm,Fri9-3pm(lines4.30pm)
OOHSecurity [email protected]
Spire (02380)775544or#7473direct
---------� 20
SpireICU 2297 SpireHDU2353
SpireICU (02380)764353
Ward1 2373/4 Ward2 2372
Pathology 2328
IT: HelpDesk (IT) 6000
JAC 4190
[email protected] bl1800
PACS 4390
Metavision 4496
CLWRota uhs.clwrota.com
---------� 21
-PACSShortcutforWRs:
ThesecanbefoundinWorklists-->RoleWorklists-->Clinician-->Wards-->CICUlessthan3days
ThiswillpickupallpaVentswhohavehadanyscans(includingCXRs)inthelast3days-fairlysensiVveforpaVentswhoareontheCICUcurrently
-MetavisionTeam:
CharliePugh,RyanBeecham,Sophie,Ma~Cordingly:
Ext4496/[email protected]
-Desktop/ipadLogin:
www.ccmv.uk
Scheduled mee?ngs:
MonAM-CardiacM+M(1stofMonth,7.30am)
TuesPM-SPR/fellowsTeaching(pm)
---------� 22
WedAM-EchoTeaching(7.30am)
FridAM–CardiacEdMeeVng(7.30am)
--------------------Noncardiac:-------------------------------------
FridAM–CardiologyGrandRound08:30,heartbeat
CardiacMDT
TAVIMDT
AorVcMDT–1st+3rdTuesdays/month(GMToffice)
Thoracic/RespiratoryRadiologyMeeVng(BigScreen)–TUESlunchVme,FridayPM
Management: CaseManagers 8686/5333
bl2166
BedManager(Cardiac) bl2365
Matron’soffice(Jenny/Kate)5943/pa1846
FionaLidell 8727/pa4241
---------� 23
Site(JakeorSarah) 3531
MaterialsManagement(Daryl) 3561
Useful Codes: (Writedownyourownusefulcodeshere…
Ch. 2 – Cardiac Theatres (Periopera?ve)
---------� 24
Preopera?ve Assessment:
Premeds(guideonly):
>80years:
-Oxygen
-Oramorph5-10mg(ornone)
-Temazepam5–10mg(ornone)
70-80years:
-Oxygen
-Oramorph10-20mg
-Temazepam10-20mg/Lorazepam1mg
---------� 25
<70years:
-Oxygen
-Oramorph10-20mgORMorphIM5-10mg
-Lorazepam1-2mgORTemazepam20mg
OtheropVons:
-hyoscine0.2-0.4mgIM
-*CauVonobese/elderly*
Anaesthe?c Room:
‘Standard’Drugs(subjecttovaria6on):
-Fentanyl1000(20mLsyringe)
-Midazolam10mg(10mLsyringe)
-Musclerelaxant–PANC/ROC/VECuronium
---------� 26
-Saline(10mLsyringe)
-PhenylStrong=10mg/10mL
-Phenylweak=100mcg/mL
-TranexamicAcid2g(20mLsyringe)+1g(10mL)
-Cefuroximex2(1.5g+1.5g)
-Heparin300mcg/kg
-Propofol1%10mL+50mLviapump
(2ndLineAbx=Vancomycin1g+Gent120-160mg)
EquipmentChecks(standard):
-TOEMachineworking/on+probeavailable
-AnaestheVcmachinecheckx2
-Metavisioncheckon/workingx2
-HaemocronJunior(ACT)
-Doubleplate(Art/CVC+spare),lines,fluids
---------� 27
-BIS/NIRS/DCVPads-ifindicated
-Pacingboxba~ery+Defibsworking
-Warmer(indi+/-B.Huggerx2)
DHCA(Arch,dissec6on,descendingAorta):
-Considerdexamethasone0.5mg/kg
-ICE
-NIRS
-ArteriallinespreandpostArch(red=proximal)
-Linespli~er
TATAVI:
-Asperstandardopenprocedurebutheparin100mcg/kg
-Bodyguardpump(yellow)+Bupivicaine0.125%8mL/hrtoprescribeonJAC(extrapleural=Localother)+arrangeviaAcutepainservice(bleep2974)
---------� 28
-Norad4mg/50mLatstart
-SeecathlabanaestheVcroomwallforfurtherinformaVon+equipment–ref:TATAVIv9b
TFTAVI:
-Midazolam5mg/5mLsyringe
-Fentanylx2ampoules(unopened)
-Rocuronium100mg/10mLsyringe
-Strong/Weakphenyl
-Propofol1%in20mL/50mL(viaTIVAset)
-Phenyl100mcg/mL50mL(viaTIVASet)
-Cefuroxime1.5g
-Lidocaine1%2mLsyringe
-ConsiderBupivicaine0.25/0.5%x3vials10mLsforblock
-Protamine(atend)
---------� 29
-SeecathlabanaestheVcroomwallforfurtherinformaVon+equipment–ref:TFTAVIv9b
EP: -Midazolam1-2mg2mLsyringe
-Fentanyl100-200mcg5mLsyringe
-Propofol1%20mL
-ROC/VECuronium
-Dexamethasone/ondansatron+/-paracetamolIV
-Phenylephrineinfusion+10mL+pump
-Bluevalve,NOT3wayoctopusforIV–usedoublelinespli~erinsteadasnofluidflowthroughoctopus
-Reversalagent
-Fluidshanging(butmaygiveligleduetoablaVonfluids+riskHFincontextpoorLV)
-OcenlistedasAFablaVon(redo)+/-TOE.SomeVmesVTablaVonorsyndromes(WPWcommon).SomepoorLV’s
---------� 30
+/-leadextracVons(CRTD/PorSCICD).MayneedCICUbed…
TAAA:
-NAC=10gneatvia50mL+Dex0.5mg/kgifDHCA
-SeeguideforLHBcases(intheatreCAR)
-OLV+scopes/catheters
-Spinaldrain+monitoringset
-Spli~ers+longcables
(seeoverforDLTselecVon)
---------� 31
DLTSelec6on:
Averagedepthofinser6on: 29cmattheteeth,+/-1cmper10cm above/below170cmheight(Ref:SlingerP.LungSepara;onTechniques.AvailableathBp://www.thoracic-anesthesia.com/?p=20)AverageUKheight:
-Males:175.5(5’9’’),83kgvsFemales:161.6(5’3’’),70kg
Tricky6ps:
-Usevideolaryngoscope+LsideTube
-Uselargesttubepossible+fa~estexchangecatheter
-(11Fvs14Frcatheter/100cm),don’tinsertpastcarina(25cm)
-LeavebronchoscopeinTracheawhenredirecVngtube
-NoBougies!
-BronchialBlockers->Arndt/E-Z/Cohen(Vpflex)
---------� 32
-largestETTtube/4cmabovecarina/nofinaladjustmentsunVlinposiVon
ThoracicSupport:
----------------------------------------------------------------ThoracicCasemanagers 5394
TheatreS 3115
TheatreT 3120
NorthWingRecovery 3100
---------------------------------------------------------
ListsavailableviaThoracicCasemanagers
Usuallyx1inptmax,remainderDoSTCI0730
---------� 33
CPB:
Heparinisa6onpriortoCPB:
-300units/kgHeparin,followedbyACTat2-3minstocheckresponse.ACT>400secondsisneededtosafelygoontobypass.
Predic6ngHbonCPB:
-(GasHbing/dLxBloodvolume(70mLxweight))/(ptbloodvolumemL+primevolumemL)
-STANDARDPRIME=~1400mLclearfluid:
-5000iuheparin
-250-500mLCSL(lactatebuffer)
-0.5g/kgmannitol10%(400mLfor80kg)
-500mLgelofusine
---------� 34
ImprovingHbonCPB:
-Aim8-10g/dL
-AddiVonofCellsavervolume
-Bankblood
-HaemofiltraVon
-RAP(retrogradeautologousprime)
-MECC(minibypass)/Smalladultcircuit
-MUF(modifiedultrafiltraVon)
CheckswhenonPump:
1.Propofolinfusionincrease
2.Productsrequested
3.Pacemakeravailable
4.Pressorsready/drawnup
---------� 35
5.Paperworkuptodate(Metavision)
6.PremedprescribedfornextpaVent
7.PerfusionParameters(MAP>65-70/Hb/NIRS/ABG)
Coming off CPB:
CVS:
1.FixSVR(phenyl/NAinfusion)+HR(pacing)
2.Assessresponsetofilling(visual/Echo/CVC/BP)
3.Inotropy:(DA+/-Milrinone)
4.Mechanical:IABP+/-ECMO
5.Monitoring:PAcatheter
ReversalofHeparin:
-1mgProtamineper100unitsHeparin
1)Onlygiveattherequestofthesurgeons
---------� 36
2)Telltheperfusionist(‘Suckersoff’)
3)Giveslowly–ascancausesignificanthaemodynamicinstability
---------� 37
CloingTargets(Don’ttreatifnotbleeding):
1.AimHb90-100g/L
2.Aimplts>75
3.INR<1.5(Octaplex/
FFP)
4.R-Vme<8-12mmon
TEG
TEGTrace:
Ref:CurryANGandPierceJMT.ConvenVonalandnearpaVenttestsofcoagulaVon.CEACCP2007)
---------� 38
StandardTEGPagerns:
Parameter
Normalrange
(Kaolin-acVvatedsample)
Increased Decreased
R-time 8-12mm
AnticoagulantsClotting factor deficienciesSeverely low fibrinogen Hyper-coagulable conditions
K-time 2-4mmAnticoagulantsLow FibrinogenLow Platelets
High fibrinogenIncreased platelet function
α-angle 66-77o High fibrinogenIncreased platelet function
AnticoagulantsLow FibrinogenLow Platelets
MA 60-75mmHyper-coagulable states
High platelet count
Low PlateletsPoor platelet function/platelet
inhibitorsFibrinolysis
Factor deficiencies (lesser extent)
LY30 <7.5% Fibrinolysis e.g. t-PA given Anti-fibrinolytics given e.g. TXA
---------� 39
TEG6s:
TEG6machinesallowtheuseofthefollowing2cartridges:
---------� 40
• GlobalHaemostasisCartridge(Bluetopcitratedspecimentube)
• PlateletMappingCartridge(Greentopheparinisedspecimentube)
GlobalHaemostasis
Test Componenttested
Parameterofinterest
Deficiency/Abnormality
Therapy
CK(CitratedKaolin)
ClotformaVonrate
↑RVme Clo�ngfactors*
FFP/FFP96(Octaplas)/PCC(Octaplex)
CKH(CitratedKaolin+
Heparinase)
ClotformaVonratewithoutheparineffect
↓RVme(comparedwithCK-RVme)
Heparineffect(ifCKH-RVme<CK-RVme)
Protamine
CRT(CitratedRapidTEG)
ClotstrengthduetoPlateletandfibrin
↓MA Platelets(ifCFF-MAnormal)
Platelets
ClotStabilitydueto
fibrinolysis
↑LY30 Fibrinolysis TranexamicAcid
CFF(CitratedFuncVonalFibrinogen)
Clotstrengthduetofibrin
↓MA Fibrinogen Fibrinogen(Cryoprecipitateor
FibrinogenConcentrate)
*InthepresenceofHeparin(whereCKH-RVme<CK-RVme),refertoCKH-RVmeforclo�ngfactoradequacy.
---------� 41
‘Product’ Types:
Calciumgluconate10%Clo�ngfactorIV.Chelatedbycitrateinbloodproducts(includingpackedredcells,platelets,octaplas,andoctaplex).Willtypicallyrequirereplacementpostcitratedblood/producttransfusion.Alsoincreasesinotropy.AimionisedCalcium(ABG)>1.15.Cryoprecipitateasourceoffibrinogen,factorVIIIandvonWillibrandfactor.2PoolsshouldraisethepaVent’sfibrinogenlevelbyapprox1g/LFreshFrozenPlasmaThenon-cellularcomponentofblood.ContainsfactorsII,V,VII,VIII,IX,X,XI,fibrinogen,proteinsCandS,andATIII.Takesapprox.30-40minutestodefrostinthelaboratory.Novo7(rFVIIa)Off-licenceuseOctaplas(FFP96)Pathogen-reducedFFPsourcedfromoutsideUKforpaVentsbornacer1Jan1996,inordertominimisethetransmissionofvCJD.Octaplex(Prothrombincomplexconcentrate)ProthrombinComplexConcentrate=vitaminK-derivedclo�ngfactors(II,VII,IX,X)inasmallvolume(comparedwithplasmatransfusion).Platelets2hrturnaround.Onepooltypicallyraisescountby30x109/L.TranexamicAcidAnanVfibrinolyVc,whichpreventsclotlysis.
---------� 42
Ch. 3 - Echocardiography Intraopera?ve TOE Guide:
1.TurnonTOEmachine 2.InputpaVentdetails 3.ConnectECG
Includetheminimumdatasetforall
4.Followalgorithms(seefollowingpages): a.GeneralOverview+LV/RV b.AVR–structural/dopplerviews c.MVR–UsuallyMR+/-TVA/LAAO d.LAAO+/-otherstructures
Adaptedfrom:WheelerRetal.2015.Aminimumdatasetforastandardtransoesophagealechocardiogram:aguidelineprotocolfromtheBriVshSocietyofEchocardiography.EchoResearchandpracVce.Dec1;2(4):G29-45
---------� 43
Notes–TheseguidesareNOTcomprehensive.Eachalgorithmdesignedtocoverstructurefora‘quick’procedureomthese�ngofadultacquireddisease.IffurtherinvesVgaVon/detailsrequired,toundertakefurthermeasurements.
---------� 44
General Overview:
Image(2D): Reference:
Territories:
1.Pullbackprobeslightly2.LVOT/MitralCFD(sameVmeifrush)3.OrientateAVtocentreofview4.Omniplaneangle->50°forAVSAX(seeAVRprotocol)…
�
�
---------� 45
‘AVRProtocol’(ifAS/ARmainproblem)
‘MVprotocol’(ifMR/MS)mainproblem+/-TVA+/-LAAO
‘LV/RVprotocol’ifIHD
AVR Protocol (Structural Views):
---------� 46
Image(2D): Aims/Ref:
� 1.Inspectleaflets
(movement,thickening,calcium)2.CountnumbercuspsBi/Tri/Quad3.Planimetrymid-systoleforAVA4.CFDAnyRegurgitaVon/where?
�
�
120
50
135
LRN
LVOT
LA
-Annulus-Sinus-STJ-AscAorta
Mid-syst
(Mid-syst0.5-1cmfromvalveorifice
INFLAT
ANTSEPT
ARR?>5.5cmor>5.0cmifsyndrome>4.5cmifothersurgery
A
E
---------� 47
DimensionlessIndex(SimilartoVelocityraVo):
-VTILVOT/VTIAV(<0.25=severe)
OR..
AVR Protocol (AS doppler views): AVR Protocol (AR doppler views):
Image(2D): Aims/Ref:
�
�
�
�
�
---------� 48
---------� 49
Image(2D):Aims/Ref:
� 1.Venacontracta2.Jetwidth/LVOTdiameter%3.Lengthjet+describedirecVon
�
�
120 Normal=<2.0m/sec
Otherparameters:
-EROA(cm2)≥0.30=severe-RegurgfracVon(%)≥50=severe
*Nyquistlimit50-60cm/s*
LV Assessment:
---------� 50
INF
INFLATIS
AS
ANT
AL
1. 2.
Em
Am
AE
Em/Am
1-2
<1
<1
<<1
E/Em(Lateral)<10Norm>10Mod
E/Em(Septal)<8Norm>15Mod
Inflow
N
Mild
Mod
Severe
SystolicblunVng
---------� 51
Mitral valve Protocol 1 (2D Views):
---------� 52
Angle:
Tips: Image(2D):
ME0
-Annulus/leafletmorphology/leafletmoVon/Sub-valvularapparatus-Pathology-A1/P1(Withdrawal/anteflexion)-A3/P3(InserVon/retroflexion)-Commissure(anterolateral)
ME60
-AssessP3/A2/P1-Majoraxisdimension(enddiastoleandendsystole)-VisualinspecVonofMR/MS
ME90
-AssessP3/A3,A2,A1-commissure(posteriomedial)-VisualinspecVonofMR/MS
ME120
-Minoraxisdimension(enddiastoleandendsystole)-VisualinspecVonofMR/MS
TG0
-A1,A2,A3Bo~omtotop-P1,P2,P3Bo~omtotop
�
�
�
�
�
---------� 53
MV Protocol 2 (RV +/- TVA):
---------� 54
Image(2D): Aims:
� -RVsize(Enddiastole):
-@base<4.2-@midpoint<3.5-length<8.6cm
-TricuspidValve:-Leaflets(Ant/Sept)-Annulussize(EDD+ESD):
� -CFDTR:Mild<1cm/narrowjet,severe
=wide/largejet-CWjet:soc/slow=mild,dense/variable=intermed,dense/steep=severe
50
120
PostLeaflet
SeptorAntLeaflet
RVRA
(TGRVInflow)SeptorAntLeaflet
PostLeaflet
PApressures
TAPSE>16mm
LAAO:
LAATypes/Morphology:
ME2Ch(90)
2D -LAAassessment(inatleast2planes).-AssesstheextentofLAAcavity+EmptyingvelociVes
MELAA(60-130)
2D
CFD
PW
-PWtoprox1/3rd-ClotassocwithvelociVes<20cm/s-Assess‘coumarinridge’-OffCPBconfirmclip/occlusiondevice
�
---------� 55
Other Structures:
---------� 56
EustachianValve(lec)+CristaTerminalis(Right)
CoronarySinus:-Normal12mm+/-2mm->15mmHg,suspectPAPVD
Prosthe?c Aor?c valves at UHS:
PericardialValveswithleafletsinsidethestent:
1.Perimount-Carpen6er-Edwards
-Bovinepericardialleaflets
-CoCralloystent-Polyestercloth,siliconerubbersewingring-19mm–29mmsizes(odds)-Variant=Magnavalve(23%greaterEOA)
2.PerimountMagnaEase–Carpen6er-Edwards-Lowerprofile:easesinserVon+aortotomyclosure-Supra-annulardesign(opVmalhaemodynamics)-Sleekcommissureposts(easeinserVon/knottying)-Suturemarkers(orientaVon+sutureplacement)-LowStentBase(coronaryosVaclearance)
PericardialValveswithleafletsoutsidethestent:
1.CrownPRT–Sorin-Bovinepericardiallayermountedoutsidestent
Gradient
19mm 21mm 23mm 25mm 27mm 29mm
Perimount
Peak 32.5±8.5
24.9±7.7
19.9±7.4
16.5±7.8
12.8±5.4
N/A
Mean 19.5±
5.5
13.8±
4.0
11.5±
3.9
10.7±
3.8
4.8±2.
2
N/A
---------� 57
-Flatprofile(lowerknotsandcoronaryclearance)
2.Trifecta-StJude
-‘LinxACtechnology’(anV-calcificaVon)-Tissuebovineleaflets-Titaniumalloystent
Composite:
1.BioIntegral-Compositerootconduitwithporcinevalve
Mechanicalbileaflet:
1.MCRIOn-X(Aor6cshown)
-PTFESewingring-PyrolyVccarboncoaVng-Leafletguards,‘flared’inlet+Actuatedpivotdesign(90˚opening)-LowerINR1.5-2(longtermmgtonly)-MostcommonlyusedinUHS
Gradient
19mm 21mm 23mm 25mm
On-
X
(AorVc)
Peak 21.3±
10.8
16.4±
5.9
15.9±
6.4
16.5±
10.2
Mean 11.8±
3.4
9.9±3.
6
8.6±3.
4
6.9±4.
3
EOA(c
m2)
1.5±0.2
1.7±0.4
1.9±0.6
2.4±0.6
---------� 58
2.CarbomedicsTopHat–Sorin-Supra-annularaorVcvalvewithgoodhaemodynamics-AlternaVvetoaorVcenlargement
DataadaptedfromEchoCalc.BriVshSocietyofEchocardiography.2015.Availableath~ps://itunes.apple.com/gb/app/echocalc/id468166426?mt=8
Gradient
21mm 23mm 25mm
Toph
at
Peak 30.2±
10.9
24.2±
7.6
NA
Mean 14.9±
5.4
12.5±
4.4
9.5±2.
9
EOA(c
m2)
1.2±0.
3
1.4±0.
4
1.6±0.
32
---------� 59
TOE: Map of views TorontoGeneralHospitalDepartmentofAnaesthesiaandPainMedicine.2008.
Availableath~p://pie.med.utoronto.ca/TEE/TEE_content/assets/PDF/TEE-help-sheet-100910-high.pdf
---------� 60
�
20 Standard TOE views FromShanwiseJetal.ASE/SCAguidelinesforperformingacomprehensive
intraoperaVvemulVplanetransesophagealechocardiographyexaminaVon:recommendaVonsoftheAmericanSocietyofEchocardiographyCouncilfor
IntraoperaVveEchocardiographyandtheSocietyofCardiovascularAnesthesiologists
TaskForceforCerVficaVoninPerioperaVveTransesophagealEchocardiography.AnesthAnalg1999;89:870–884
---------� 61
Southampton CICU Focused TOE
---------� 62
�
Chamber and func?on quan?fica?on
(Ref:Masanietal.BriVshSocietyofEchocardiographyEducaVonCommi~ee.Echocardiography:guidelinesforchamberquanVficaVon.G407.BriVshHeartfoundaVon.2011.Availableat:h~ps://www.bhf.org.uk/publicaVons/tests-for-heart-condiVons/echocardiography-guidelines-for-chamber-
quanVficaVon-poster)Note:ThefollowingtablesarebasedonTTEimaging.
Le\ atrial size
�
---------� 63
Le\ Ventricular size and func?on
!
Aor?c Stenosis (reference):
AVA (cm2)
Indexed valve area (cm2/m2)
Peak velocity (m/s)
Peak gradient (mmHg)
Mean gradient (mmHg)
AHA ESC BSE
---------� 64
(ref: Vegas, A. Perioperative Two-Dimensional TOE. Adapted from: Baumgartner H et al. J Am Soc Echocardiogr 2009;22:1-23.) (ref: Vegas, A. Perioperative Two-Dimensional TOE. Adapted from: Zoghbi W et al. J Am Soc Echocardiogr 2003;16;777-802.)
Aor?c Regurgita?on (reference):
Normal
3.0-4.0
1.4-2.2 8-20
Mild >1.5 >0.85 2.6-2.9 20-40 <20 <30
Mod 1.0-1.5
0.6-0.85
3.0-4.0 40-70 20-40 30-50
Severe
< 1.0 <0.6 >4.0 >70 >40 >50
Method Mild Moderate Severe
Jet/LVOTwidth* <25% 25-64% >65%
PHT(ms) >500 500-200 <200
DescendingAoReversal Earlybrief Intermediate Holodiastolic
VenaContracta*(mm) <3 3-6 >6
EROarea(cm2) <0.10 0.1-0.29 >0.3
---------� 65
Right ventricular size and func?on
RequrgitantVolume(cc) <30 30-59 >60
RegurgitantFracVon(%) 20-30 30-49 >50
*Nyquistlimit50-60cm/s
---------� 66
MitralStenosis:(EAE/ASA Guidelines)
(ref: Vegas, A. Perioperative Two-Dimensional TOE. Adapted from: Baumgartner H, et al. J Am Soc Echocardiogr 2009;22:1-23)
MitralRegurgita6on
(ref: Vegas, A. Perioperative Two-Dimensional TOE. Adapted from: Zoghbi W et al. J Am Soc Echocardiogr 2003;16;777-802.)
Valve area(cm2)
Mean gradient(mmHg)
PHT(msec)
Peak pulmonary artery P(mmHg)
Normal 4-6 40-70 20-30
Mild >1.5 <5 70-150 <30
Mod 1.0-1.5 5-10 150-200 30-50
Severe < 1.0 >10 >220 >50
Method Mild Moderate Severe
CWDopplersignalstrength Faint Mod Dense
Jetareamapping(cm2)* <4 4-10 >10
PulmonaryvenousDoppler(Swave) Normal Blunted Reversed
VenaContracta*(mm) <3 3-6 7+
EROarea(cm2) <0.2 0.2-0.39 >0.4
PISAradius(mm)(Nyquistat40cm/s) <4 4-9 >10
RegurgitantFracVon(%) <30 30-49 50+
*Nyquistlimit50-60cm/s
---------� 67
Le\ ventricular diastolic func?on (deflecVonsbasedonTTEacquisiVon)
---------� 68
�
Ch. 4 - Postopera?ve:
Bleeding/Clo�ng/ICUCare
---------� 69
Cardiac Transfusion Protocol
�
---------� 70
Haemofiltra?on:
Dose:35ml/kg/hror>25ml/kg/hrsufficientformost.Highervolumesmayreducevasopressorrequirements,butincreaseelectrolytedisturbances.
Noevidenceforactualvsidealweight
CRRTachieves~25-50mL/minCrCl
Replacementfluids(prescribe):
-HemosolBO
-Prismasol4
An6coagula6on:
1.Heparin.UsuallyavoidgivingheparinbolustopaVent.Juststartinfusion.AimaPTT1.5-2.0
2.Inpeoplewithheparin-inducedthrombocytopenia,considerusing:
---------� 71
A.Epoprostenol
CompaVblewith0.9%salineonly
Dose:1-5nanograms/kg/min
PreparaVon:MakeupaconcentraVonof2mcg/ml(100mcgin50mlsyringe).Runat:
Note:2mcg/kgdilutedsyringesareonlystablefor12hinthefridge.
B.Argatroban(directthrombininhibitorIVprep)=licensed
-NoIVbolus
-Infusion2mcg/kg/min->RptaPTT4hrdoseadjustment
PaVentWeight(kg) ml/h[4ng/kg/min] ml/h[5ng/kg/min]
50 6.0 7.5
60 7.2 9.0
70 8.4 10.5
80 9.6 12.0
90 10.8 13.5
100 12 15.0
---------� 72
-MonitorAPTT(1.5-3)
-HepaVcmetabolism(LiverFailure0.5mcg/kg/minstart)
C.Heparinoids(DanaparoidIVprep)=licensed
-IndirectAnVXa+/-li~lethrombin
-24halflife
-MineffectonaPTT/NoneonPT
-MonitorwithAnVXaAssayifRenalFailure
-750unitsBDorTDS*prophylaxis
-1250–3750unitsbolusIVthen400units/hrinfusionfor4hrs,then300/hrfor4hrs,then150-200units/hrmaintenanceIV*Treatment
D.Citrateregional
-Remember,separateDVTprophylaxisrequired.
-JuststartedusinginCICU..
---------� 73
E.Fondaparinux(notlicensed)
F.Bivalirudin(notlicensed)
G.Lepirudin(notlicensed/availableatUHS)
Low Cardiac Output State:
Monitoring:Cardiacoutput=SVxHR (4–8L/min)CI=CO/BSA (<2,2–2.5,>2.5L/min/m2)PAWP≤15mmHg
Causes:PoorLV,preload,highacerload,rhythm+rate(Physiology)Airembolism/tamponade+/-bleedingStunningPerioperaVveMIIncompleterevascularisaVon/grackinkingPHTNOther:SAM(MVrepairs),drugreacVon,HOCM,vasoplegia
---------� 74
SupportforLowCO/ECMO:-Inotropes,IABP,ECMO-ECMOmaintenance(mainlyonCICU):HCT40-45%Plts>80ACT180-240LowTVIPPV<5mL/KgNewdoseforECMOcannulaVon75iu/kgIf>30minsunVlonECMO,repeatACTandgiveextra25iu/kgifACT<300
Airentrainment(*Emergency*):
Diagnosecause/site+purgepump+circuit
1.Clamparterialline2.Clampvenousline3.stoppump4.Runcystalloidintocircuit+drain/purge5.manipulatepumpheadtoencourageairtowardsoxygenator6.Onceairdrained->closetubingtobag+openAVbridge,inspectforair
---------� 75
Pulmonary HTN:
NormalPAP:PAP <25/10mmHgPAPm 14±3mmHg(<20mmHg)
pHTN: Pre-capillaryPH PAPm≥25mmHg
PAWP≤15mmHgPost-capillaryPH PAPm≥25mmHg PAWP>15mmHg
Classifica;oncomplicatedandmanydifferentsubsetsofdiseasewithspecificmanagement–seekadvice.
Classifica6on(Non-congenital):1.PAH(idiopathicvsassocwithsystdisease)2.PAHduetolecheartdisease3.PAHduetolungdiseases/hypoxia4.ObstrucVve/thromboembolic5.PHunclearormulVfactorialmechanisms
ICUTreatment(Seekexpertadvice!):
A) Maintainpa6ent’snormaltherapywherepossibleB) MaintainPAPm25mmHg<SystemicMAPC) ForrisingPAPs,addin:
1.NO:5-25ppmviaNoxbox2.Prostanoids:
---------� 76
-Iloprostnebs(20mcg3hrly)-IloprostIV(50mcgin250mL5%dextrose)-0.5-2mcg/kg/min(approx.12-48mL/hour).-Increasedose½hourly3.Vasodilators-PDEType5inhibitors:-Sildanefilpo/NG(20mgTDS,increaseupto50mg)4.Endothelinreceptorantagonists:-Ambrisentanpo/NG(5mgod,increasedto10mgod)-N.B.Livermetabolised4.Surgical/CardiologyInterven6on:-Balloonatrialseptostomy>failuremaxmedtherapy-+/-lungtransplantaVon
---------� 77
Heparin-induced thrombocytopenia 4T’sassessmentpointsystem
---------� 78
Category 2points 1point 0points
Thrombo-cytopenia
>50% fall or Nadir of
20-100 x 109
/L
30% - 50% fall or Nadir of 10-19x 109/L
<30% fall or Nadir of < 10 x
109
/L
Timingoffall Days 5 – 10 or less than or equal 1 day if there is heparin exposure within the past 30 days.
Greater than day 10 or unclear or less than 1 day if heparin exposure within past 30 – 100 days
Less than or equal to 1 day with no recent heparin therapy
Thrombosis(orothersequelae)
Proven thrombosis, skin necrosis, or other heparin bo- lus, acute systemic reaction
Progressive, recurrent, orsilent thrombosis; erythematous skin lesions
None
Othercauses None evident Possible Definite
Score 0-3 Low probability
4-5 Intermediate probability
6-8 High probability
Steele J, Kadosh B, Gulkarov IM, Salemi A (2011) Heparin Induced Thrombocytopenia and Cardiac Surgery: A Comprehensive Review. J Blood Disord Transfus S2:003.
---------� 79
---------� 80
Ch. 5 – Congenital informa?on
A classifica?on of congenital lesions
1. ‘Simple’ le\-to-right shunt (Qp > Qs), with increased pulmonary
blood flow
Atrialseptaldefect
Ventricularseptaldefect
Atrio-ventricularseptaldefect
Patentductusarteriosus
Aorto-pulmonarywindow
AlargeVSDorAVSDcandemonstratemorecomplexbalancingbetweenQp:Qs.
AlargereducVoninSVR,orapulmonaryhypertensivecrisisaretwoexamplesthatcausealec-to-right(Qp>Qs)shunttoreversetoa
right-to-lecshunt(Qp<Qs),resulVngincyanosis.
---------� 81
2. ‘Simple’ right-to-le\ shunt (Qp<Qs), with decreased pulmonary
blood flow & cyanosis
TetralogyofFallot
Pulmonaryatresia
Tricuspidatresia
Ebstein’sanomaly
3. ‘Complex’ shunts, with complex mixing of pulmonary and systemic
blood, and thus a complex interplay between pulmonary (Qp) and systemic (Qs) blood flow
ExamplesofparallelcirculaVonsaremarkedwithan*
TransposiVonofthegreatarteries*
Truncusarteriosus*
Double-outletrightventricle*
HypoplasVclecheartsyndrome*
PresenceofaBTshunt*
Totalanomalouspulmonaryvenousdrainage
---------� 82
4. Obstruc?ve lesions
CoarctaVonoftheaorta
InterruptedaorVcarch
PulmonaryoraorVcstenosis
---------� 83
Qp:Qs thera;oofpulmonarytosystemicbloodflow
SimplifiedshuntcalculaVon
�
S=saturaVon,sa=systemicarterial,mv=mixedvenous,pv=pulmonaryvein,pa=pulmonaryartery
Note:Inthepresenceofashunt,SmvO2≠SpaO2
FormulaforesVmaVngmixedvenousSatswhencalculaVngashunt:
Inadults:�
Ininfants/children:consideraccepVngSmv≡SSVC
Qp :Qs = (SsaO2 − SmvO2)(SpvO2 − SpaO2)
Smv =(3SSVC + SIVC )
4
---------� 84
ForauniventricularheartwithonlyaorVc-pulmonarybloodflow
�
Inter-atrialshunts:Qp:Qsisdependentprimarilyonthecompliancedifferencesbetweenthetwoventricles.
Inter-ventricularorgreatvessellevelshunts:Qp:QsisdependentprimarilyontherelaVveresistancesofthepulmonaryandsystemiccirculaVons.ManipulaVonstrategiesinclude:
Toincreasepulmonarybloodflow:ReducePVR(+/-increaseSVR)
Todecreasepulmonarybloodflow:IncreasePVR(+/-decreaseSVR)
Qp :Qs = (SsaO2 − SmvO2)(SpvO2 − SsaO2)
---------� 85
---------� 86
Factors increasing PVR Hypoxia
Hypercarbia
Acidosis
Hypothermia
SympatheVcsVmulaVonorcatecholamines
Loworhighlungvolumes,oratelectasisorhyperinflaVonrespecVvely
Highairwaypressures
Factors decreasing PVR IncreasingFiO2
DecreasingPaCO2
Alkalosis
Avoidanceofhypothermia
Pulmonaryvasodilators(iNO,Milrinone,Sildenafil)
Avoidanceofcatecholaminesurges(pain,sympatheVcsVmulaVon)
LungvolumeatfuncVonalresidualcapacity
---------� 87
A Possible circulatory troubleshoo?ng strategy post Norwood based on SvO2: SaO2 SvO2 Qp:Qs Suggestedinterven6on
80 60 1 None;weansupportslowly
80 40 2 DeepensedaVon/warmth/vasodilator
70 50 0.67 Resolveatelectasis,raiseSVR
70 40 1 Raisecardiacoutput,raiseHb,reduceO2consumpVon
70 20 2 Raisecardiacoutput,lowerSVR
60 40 0.5 Resolveatelectasis,raiseSVR,consideriNO,considershunt
augmentaVon
87 70 1.5 Weansupport
87 40 3.6 DeepensedaVon,vasodilaVon,considershuntrestricVon
---------� 88
Troubleshoo?ng differen?al diagnosis post SCPA/Glenn
Status
PAP LAP TPG SpO2 Ae6ology
Normal
10-15 2-6 <10 80±5 Ideal
ElevatedPAP
>15 2-6 >10 <75 HighPVR;PAorPVobstrucVon
ElevatedLAP
>15 >8 <10 <75 VentriculardysfuncVon,sub-AS,AVVR,tamponade
Cyanosis
10-15 2-6 <10 <75 Decreasedcerebralbloodflow;PVdesaturaVon,decompressingveins;hypovolaemia,anaemia
---------� 89
Troubleshoo?ng differen?al diagnosis post Fontan
Status PAP LAP TPG SpO2 BPsys Ae6ology
Normal 10-15 2-6 <10 95±5 85-95 Ideal
DecreasedPAPandLAP
8-10 0-4 <10 90±5 <80 Hypovolaemia
ElevatedPAP >15 2-6 >10 90±5 80±5 HighPVR;PAorPVobstrucVon
ElevatedLAP >15 >8 <10 90±5 80±5 VentriculardysfuncVon,AVdissociaVon,AVVR,tamponade
Cyanosis 10-15 2-6 <10 <85 85-95 ExcessivefenestraVonsizeorFontanbaffleleak;PVdesaturaVon;decompressingveins;hypovolaemia;anaemia
---------� 90
Congenital heart disease – An introductory glossary of terms
Anomalous pulmonary venous drainage: partial - at least one, but not all, pulmonary veins connect to the right heart, often via the superior or inferior vena cava, leading to varying degrees of left-to-right shunt (Qp:Qs>1). Total - all pulmonary veins abnormally drain to the heart. Types include: supracardiac – where they eventually drain to the SVC, intracardiac – where they drain through the coronary sinus, and infracardiac – where they drain beneath the diaphragm to the portal venous system.
Aortopulmonary window: a window (communication) between aorta and main or right pulmonary artery. May be associated with interrupted aortic arch.
Atrial septal defect: types include patent foramen ovale (PFO), secundum, primum (a type of AV defect), sinus venosus (superior: at SVC to RA junction, associated with PAPVD of right upper and middle PVs; inferior: at IVC to RA junction, associated with PAPVD right lower PV), coronary sinus (unroofed coronary sinus leading to communication between left atrium and coronary sinus). Leads to left-to-right shunt.
AVSD: atrio-ventricular septal defect due to incomplete fusion of the endocardial cushions, leading to malformation of the mitral and tricuspid valves, atrial and ventricular septal defects. A common atrioventricular valve straddles the ventricular septum.
Balanced circulation: equal pulmonary and systemic blood flow (Qp:Qs = 1).
---------� 91
Bidirectional Glenn/bidirectional cavopulmonary shunt/superior cavopulmonary shunt (SCPC)/hemi-Fontan: SVC disconnected from RA and anastomosed to PA, causing pulmonary blood flow to comprise SVC venous blood. It is bidirectional because SVC blood is free to flow through either right or left PA (in contrast to a unidirectional/original Glenn shunt where the SVC was directly anastomosed to the right PA that had been disconnected from the main PA, thereby preventing SVC blood from flowing to the left PA).
Blalock-Taussig (-Thomas) shunt (BT shunt): original - transection of subclavian artery and end-to-side anastomosis to ipsilateral pulmonary artery. Modified - a graft conduit placed between either the innominate or subclavian artery and the ipsilateral pulmonary artery. Designed to allow some pulmonary blood flow through a systemic-to-pulmonary connection.
Brom repair: a 3-patch technique that allows repair of supra-aortic narrowing with enlargement of all 3 sinuses.
Carpentier’s procedure: a method for tricuspid valve repair of Ebstein’s anomaly, characterised by mobilisation of anterior leaflet, vertical plication of the atrialised RV, advancement of the anterior leaflet across the plicated area to reduce orifice size, and insertion of an annular ring for additional valve strength.
Central shunt: small tubular connection created between ascending aorta and main pulmonary artery. Designed to provide some pulmonary blood flow through a systemic-to-pulmonary connection.
Coarctation of the aorta: a narrowing of the thoracic aorta, usually distal to the left subclavian artery. Associated with bicuspid aortic valve.
---------� 92
Cone procedure/reconstruction: a method for tricuspid valve repair of Ebstein’s anomaly, characterised by mobilisation of valve leaflets, maximisation of leaflet tissue through delamination of the valve tissue from the myocardium whilst maintaining chordae attachment, rotation and suturing of the leaflet complex to create a cone with base at the TV annulus and vertex in the right ventricular apex, and plication of atrialised RV.
Cor triatriatum: a restrictive membrane in the left atrium, dividing the atrium into two chambers. Blood from the upper chamber, where the pulmonary veins enter, drains into the lower chamber through one or more orifices in the membrane, with symptoms dependent on the degree of restriction through the membrane.
Damus-Kaye-Stansel operation: a proximal PA to aorta anastomosis (above their respective valves). It provides systemic flow in situations where there is LVOT obstruction or subaortic stenosis in functional univertricular hearts. Usually combined with either a BT shunt or a RV-PA conduit, which supplies pulmonary blood flow.
Double inlet left ventricle: both atria drain into a single ventricle, which is commonly connected to an additional hypoplastic ventricle via a bulboventricular foramen. The most common subtype is a double-inlet LV, which is anatomically right-sided, and has ventricular-arterial discordance (TGA).
Double outlet right ventricle: a defect in which both pulmonary artery and aorta arise from the right ventricle. A VSD is present, positioned either in a sub-pulmonary, sub-aortic, doubly-committed, or remote location. The resultant physiology can mimic that of tetralogy of Fallot, transposition of the great arteries, or a VSD, depending on the relation between the position of the VSD to the great arteries.
Ebstein’s anomaly: abnormality of the tricuspid valve resulting in abnormal downward and rotational displacement of the valve orifice into the RV, with
---------� 93
atrialised portion of the RV between the annulus and abnormal leaflet attachments.
Fontan operation/Fontan completion/total cavopulmonary connection (TCPC): final stage in univentricular palliation (after a previous Glenn/SCPC/hemi-Fontan procedure. The IVC is connected to the PA in one of 3 ways; originally through a RA-PA direct anastomosis, or through a lateral tunnel within the RA, or through an extra-cardiac conduit (now most common approach). A fenestration between the IVC and RA may be created to provide a right-to-left ‘pop-off’ pathway from the cavopulmonary circuit to the heart in order to lower the pressure in the circuit, albeit at the expense of lower saturations.
Heterotaxy: a complex syndrome of malformation, due to abnormal sidedness of thoracic and abdominal organs. Potential abnormalities include atrial or lung isomerism, single ventricle, poly- or a-splenia, bilateral or persistent left SVC, TAPVD, left-sided or interrupted IVC, and intestinal malrotation.
Holmes heart: a specific sub-type of DILV, with a hypoplastic morphological right ventricle, and normally related great arteries.
Interrupted aortic arch: interrupted or atresic arch, leading to complete distal disruption or obstruction to flow.
Jatene procedure: this procedure is an arterial switch operation and is a definitive treatment for transposition of the great arteries. Both the aorta and pulmonary arteries are transected. The aorta is anastomosed to the residual proximal pulmonary artery, which becomes the neo-aorta. The distal pulmonary artery is anastomosed to the residual proximal aorta. Commonly a Lecompte manoeuvre is carried out during this step. Crucial to the success of the procedure is the successful transfer of the coronary origins from the native aorta to the neo-aorta.
---------� 94
Konno procedure: in order to relieve LVOT obstruction associated with aortic valve annulus hypoplasia, the aortic valve is excised and an incision in the ventricular septum is made and patched open. The creation of a widened LVOT allows a larger aortic valve to be used. This can be with either a mechanical (Konno-Rastan), homograft, or autograft (Ross-Konno) replacement.
Lecompte manoeuvre: the distal main pulmonary artery is brought anterior to the aorta so that the left and right PA bifurcation straddles the anterior ascending aorta.
MAPCAs: major aorto-pulmonary collateral arteries. These vessels are likely dilated bronchial arteries and provide a degree of pulmonary blood flow. They can provide a portion or all pulmonary blood flow depending on the degree of pulmonary arterial flow, or presence (or absence) of alternative conduits for pulmonary blood flow (e.g. PDA, BT shunt). They are prone to stenosis.
Mustard procedure: an atrial switch procedure for patients with transposition of the great vessels that creates an intra-atrial baffle made of native pericardium or synthetic material. This redirects pulmonary venous blood through the tricuspid valve into the right ventricle, and systemic venous blood through the mitral valve into the left ventricle. By surgically creating atrio-ventriclular discordance, physiologic (but not anatomical) correction is achieved.
Norwood procedure: first of a three stage palliative process for patients with univentricular hearts. It involves transection of the pulmonary artery, amalgamation of the proximal pulmonary artery with aorta, aortic arch augmentation, atrial septectomy, and provision of pulmonary blood flow either through a systemic-to-pulmonary artery shunt (BT shunt), or via an RV-PA conduit (Sano shunt/modification).
Patent ductus arteriosus: Persistence of a patent ductus arteriosus results in left-to-right shunt from aorta to pulmonary artery, and can lead to pulmonary overcirculation, pulmonary hypertension and heart failure.
---------� 95
Potts shunt: fenestration-type direct communication created between descending aorta and left pulmonary artery. Designed to provide some pulmonary blood flow through a systemic-to-pulmonary communication.
Rastelli procedure: in situations such as certain sub-types of double outlet right ventricle, LV outflow is accomplished by routing blood across a VSD patch, which serves as a baffle. An RV-PA conduit provides pulmonary blood flow.
Ross procedure: for some cases of aortic valve replacement, the patient’s own pulmonary valve (pulmonary autograft) is transposed to the aortic position. A cadaveric or bioprosthetic pulmonary valve is then used to replace the patient’s native pulmonary valve. The advantage of this procedure is the superior longevity of an autograft compared with currently available homografts, and is the only option that provides the possibility of growth, thereby appealing for use in children.
Sano shunt: an RV-PA conduit.
Senning procedure: a similar procedure to the Mustard procedure, although autologous tissue from the right atrial wall or inter-atrial septum is used rather than the pericardium or synthetic material used in the Mustard procedure.
Starnes procedure: as an alternative to biventricular repair of Ebstein’s anomaly, the Starnes procedure involves patch closure of the TV, reduction atrioplasty and/or RV plication, formation of an unrestrictive ASD, and creation of pulmonary blood flow through a mBT shunt, thereby creating single ventricle physiology.
Taussig-Bing anomaly: a heart with a double outlet right ventricle with a
---------� 96
subpulmonary VSD. Left ventricular oxygenated blood is preferentially streamed into the pulmonary artery, and therefore behaves physiologically as a heart with transposition of the great arteries.
Transposition of the great arteries: in d-transposition, there is ventricular-arterial discordance, whereby the aorta arises from the right ventricle and the pulmonary artery arises from the left ventricle. Treatment historically involved either a Mustard or Senning procedure. Current definitive treatment is a Jatene procedure (arterial switch). In the rarer l-transposition (synonymous with ‘congenitally-corrected transposition’), there is both atrio-ventricular and ventricular-arterial discordance. The right atrium drains blood through a mitral valve into a right-sided morphological left ventricle, which ejects into the pulmonary artery. The left atrium drains blood through a tricuspid valve into a left-sided morphological right ventricle, which ejects into the aorta. Treatment may include a double switch, involving both a Senning and a Jatene procedure, to allow the morphological left ventricle to become the systemic pump.
Truncus Arteriosus: a defect in which the pulmonary artery and aorta exit the heart as a single trunk. There is a VSD, which the trunk overrides.
Ventricular septal defect: a defect in the ventricular septum. When large and unrestricted, this commonly leads to significant left-to-right shunting and pulmonary overcirculation. A number of types exist depending on position within the septum and relation to intracardiac structures, including inlet, outlet, perimembranous, muscular, and apical.
Waterston shunt: fenestration-type direct communication created between ascending aorta and right pulmonary artery. Designed to provide some pulmonary blood flow through a systemic-to-pulmonary communication.
Congenital references:
Andropoulos D, et al. Anaesthesia for congenital heart disease. 3rd edition. 2010. Wiley: USA.
---------� 97
Barry P, Morris K, Ali T. Paediatric intensive care (oxford specialist handbook). 2010. Oxford University Press: UK.
Everett A, Lim D. Illustrated field guide to congenital heart disease and repair. 3rd edition. 2015. Scientific Software Solutions, Inc: USA.
Lake C, Booker P. Pediatric cardiac anesthesia. 4th edition. 2004 Lippincott Williams and Wilkins: London.
Ch. 6 – Drug informa?on
Generalreferences:TomlinM,etal.Aguidetoparenteraldrugsusedonadultintensivecare.2008.SouthamptonGeneralHospital.AshleyC,CurrieA.2009.Therenaldrughandbook,3rded.RadcliffePublishing:Oxford.
An?microbials: Caspofungin:
Wt<80kg:70mgodday1,then50mgodthereacer
Wt>80kg70mgod
---------� 98
ModeratehepaVcinsufficiency:70mgday1,then35mgod
Renalimpairment/CVVH:
-GFR<10:DoseasinnormalrenalfuncVon.
-CVVHDF:Notdialysed.Doseasinnorm.renalfuncVon
Cefotaxime:
1-2gBDorTDS
MeningiVs:2g4hourly
Renalimpairment/CVVH: -GFR<10-20:DoseasinnormalrenalfuncVon -GFR<10:1gevery8-12hours -CVVHDF:Dialysed.2Gevery12hours
Cerazidime:
1-2gTDS
Renalimpairment/CVVH: -GFR31-50:1-2gevery12hours -GFR16-30:1-2gevery24hours -GFR6-15:500mg-1gevery24hours -GFR<5:500-1gevery48hours -CVVHDF:Dialysed.2gevery12hours
---------� 99
Cefuroxime:
1.5gramTDS Renalimpairment/CVVH: -GFR10-20:750mg-1.5gevery8-12hours -GFR<10:750-1.5gevery12-25hours -CVVHDF:Dialysed.DoseasinGFR=10-20
Chloramphenicol:
(IV)12.5mg/kgQDS(max1gramQDS) Renalimpairment/CVVH: -GFR<10:DoseasinnormalrenalfuncVon -CVVHDF:Notdialysed.DoseasinnormfuncVon
Ciprofloxacin:IV:200-400mgBD
oral:250-750mgBD
Renalimpairment/CVVH: -GFR10-20:50-100%normaldose
---------� 100
-GFR<10:50%normaldose(100%doseforshort periodsunderexcepVonalcircumstances) -CVVHDF:Dialysed.Oral500-750mgevery12hours.IV:200-400mgevery12hours.
Clarithromycin:
IV/oral250-500mgBD
Renalimpairment/CVVH-Usewithcau6on: -GFR10-30Oral/IV:250-500mgevery12hours. -GFR<10:Oral/IV:250-500mgevery12hours. -CVVHDF:Unknowndialysability.DoseasinGFR=10-30
Co-amoxiclav:
IV:1200mgTDS
PO:375-625mgTDS
Renalimpairment/CVVH: -GFR10-30:IV:1200mgevery12hours -GFR<10:IV:1200mgstatfollowedby600mgevery8hoursor1200mgevery12hours. -CVVHDF:Dialysed.DoseasinGFR=10-30
Co-trimoxazole(Septrin):
---------� 101
IV/Oral:120mg/kg/dayin2-4divideddoses
Renalimpairment/CVVH: -SeeRenalDrugHandbookDaptomycin:
Renalimpairment/CVVH: -GFR30-50:DoseasinnormalfuncVon -GFR<30:4mg/kgevery48hours -CVVHDF:Slightlydialysed.4-6mg/kgevery48hours.
Erythromycin:(Prokine6cuse)IV/Oral:500mgbd
Renalimpairment/CVVH: -GFR<10:50-75%normaldose.Max2gramdaily -CVVHDF:Unknowndialysability.DoseasinnormalrenalfuncVon.
Flucloxacillin:
IV/Oral:250mg-1000mgQDSUpto8gram/daymaybeusedinsevereinfecVonssuchasendocardiVs
Renalimpairment/CVVH: -GFR<10:DoseasinnormalfuncVonupto4gmaxdaily.
---------� 102
-CVVHDF:Notdialysed.Doseasinnormalrenal funcVon.
Fluconazole:
Invasivecandida:400mgIVstat,then200-400mgIV/oralod(cauVoninhepaVcandrenalfailureandinteractswithwarfarin,phenytoin,ciclosposinandtheophylline)
Renalimpairment/CVVH: -GFR<10:50%normaldose. -CVVHDF:Dialysed.400-800mgevery24hours
Gentamicin:SeeUHSmicroguide
Meropenem:
Renalimpairment/CVVH:
-GFR20-50:500mg–2gevery12hours
-GFR10-20:500mg-1gevery12hoursor500mgevery8hours
-GFR<10:500mg–1gevery24hours
-CVVHDF:1gevery12hours
---------� 103
Metronidazole:
IV500mgevery8hours Renalimpairment/CVVH:
-GFR<10:DoseasinnormalrenalfuncVon -CVVHDF:Unknowndialysability.DoseasinnormalrenalfuncVon.
Rifampicin:
600-1200mgdailyin2-4divideddoses Renalimpairment/CVVH: -GFR<10:50-100%ofnormaldose -CVVHDF:Unknowndialysability.DoseasinnormalrenalfuncVon.Tazocin(Piperacillin/Tazobactam)4.5gevery8hoursRenalimpairment/CVVH: -GFR10-20:4.5gevery8-12hours GFR<10:4.5gevery12hours-CVVHDF:Dialysed.4.5gevery8hours
Teicoplanin:
400mg12hourlyfor3doses(loading),then400mgdaily.
Renalimpairment/CVVH:---------� 104
-GFR10-20:Givenormalloadingdose,then200-400mgevery24-48hours -GFR<10:Givenormalloadingdose,then200-400mgevery48-72hours -CVVHDF:Unknowndialysability.DoseasinGFR10-20
Vancomycininfusion:
1gloadingover2hours(consider500mgif<40kg)
Thenforinfusion:makeup500mgin100mL0.9%NaCl.
CreaVnine<120=Startat13mL/hr
CreaVnine>120orCVVH=Startat8mL/hr
Doleveldailyat6am(unlessstartedwithin6hours)
Iflevel<15mg/L Increasedose/ratebynextlevelupintable
Iflevel15-25mg/L Nochange
Iflevel>25mg/L Decreasedose/ratebynextleveldownin table
Iflevel>30mg/L Stopinfusionfor6handd/wconsultantor pharmacist.
---------� 105
Seda?ves and anxioly?cs:
Chlorpromazine:
25mgIMmaxTDS(CauVoninParkinson’s,epilepsy,Myastheniagravis)
Clonidine:seebelow
Dexmedetomidine:seebelow
DailyDose
3500
mg
3000
mg
2500
mg
2000
mg
1500
mg
1000
mg
500
mg
250
mg
Equivalentrate(5mg/ml)
29
ml/h
25
ml/h
21
ml/h
17
ml/h
13
ml/h
8
ml/h
4
ml/h
2
ml/h
---------� 106
Haloperidol:
1.25-5mg(contraindicatedinparkinson’sdisease.CauVoninliverdiseaseandrenalfailure,epilepsy,andphaeochromocytoma)
Lorazepam
IV1mg
Olanzapine:
IV/IM2.5-5mgPRN(unlicensed)
Procyclidine:
2.5mg–5mg
Que6apine:
po12.5mgPRN
Clonidine
---------� 107
Introduc6on:
-PotentcentralAlpha2agonistwithweakalpha1acVvity,leadingtosedaVon,analgesia,bradycardiaandhypotension
-IncreasesTSHandGH,butdecreasesADHandinsulinsecreVon
Indica6on:
-AgitaVon/-Hypertension
DoseRange:
-300-900mcg/24hrs
-Max1200mcg/24hrs
-PO50-200mcgTDS(max300mcgatVme)
Presenta6on:
-CompaVblewith0.9%NaCland5%dextrose
-Makeup450mcgin50mls
-Runat0-6ml/h
---------� 108
Notes:
Sideeffectsinclude,hypotension,bradycardia,depression,drowsinesswithdrymouthandconsVpaVon.
Cancausereboundhypertension,tachycardiaandrestlessnessorwithdrawal.ThereforeVtratedosedownoverafewdays
---------� 109
Dexmedetomidine:
(ref:Guy’sandThomas’NHSFT)
Introduc6on:
-a2agonistsimilartoclonidine
-NotfordeepsedaVon
Indica6on:
-Failedtrialclonidine(BPdrop,HR)
-Difficultairway/extubaVon
-Highriskdelirium(PRODEX/MIDEXstudies)
-NIV(lackrespdepression)
DoseRange:
-0.4-1.4mcg/kg/hr
---------� 110
-Start0.8mcg/kg/hrmajority
-30-60minsbetweendosechangesof0.1mcg/kg/hr
-Reduceby0.1mcg/kg/hrincrements->0.4mcg/kg/hrthenstop
Presenta6on:
-100mcg/mL(10mL)->prepareto20mcg/mLconcentraVonin50mLsyringewithsaline0.9%
Shivering associated with hypothermia: Skincounter-warming
Paracetamol
Pethidine25mgIV
Magnesium
Chlorpromazine25mgIM
Opiatesincl.Meperidine50-100mgIM/IVorfentanylinfusion
---------� 111
propofolinfusion
ClonidineorDexmedetomidineinfusion
Neuromuscularblockingagents(lastresort)
Acid/base special situa?ons
Acetazolamide
Introduc6on:
-Carbonicanhydraseinhibitor.ReduceshydrogenionexcreVon,raisingurinarypHandacidifyingplasmapH
Indica6on:Rhabdomyolysis
SVmulatesrespiraVonbyacidifyingplasmapH
Treatmentofmetabolicalkalosis
DoseRange:
-IVslowly500mgBDfor3-5/7
Notes:
Causesflushing,headaches,thirstandacid/base/electrolyteimbalance,paraesthesia,ataxia,andhypervenVlaVon.
---------� 112
Contraindicated/cau6onmetabolicacidosis,tachypnoea,sulphonamidehypersensiVvity,livercirrhosis(increasesriskofencephalopathy)
Cardiovascular drugs: Adrenaline: Introduc6on:
-Alpha,Beta1+2agonist.Increasescardiacoutput,peripheralvascularresistance,coronarybloodflow,andheartrate.
-IncreasesmyocardialO2consumpVon,plateletadhesivenessandbloodcoagulaVon,bloodglucose,andisametabolicandmildrespiratorysVmulant.
Indica6on:
-ToincreaseinotropyandSVR
DoseRange:
-0.01mcg/kg/min–1.0mcg/kg/min
Presenta6on:
-NotetwoconcentraVonsavailable:
---------� 113
1mgin1mlampule(1:1000)
AND
1mgin10mlampuleorminijet(1:10,000)
-Add1mgtoatotalof50mls5%glucose.AlsocompaVblewithdex/salineand0.9%saline.
-Runat0-20ml/h.ConcentraVoncanbedouble(2mg/50ml)orquadrupled(4mgin50mls)asrequired.
Notes:
- GICUusesastrongerconcentraVon(10mgin100ml,equivalenttoquintuplestrengthCICUstrength).
- IncompaVblewithSodiumBicarbonate
Renalimpairment/CVVH:
-GFR<10DoseasinnormalrenalfuncVon
-CVVHDF:Notdialysed.DoseasinnormalrenalfuncVon
---------� 114
Amiodarone:
Introduc6on:
-ClassIIIanV-dysrhythmic,alsowithclassIacVvity
-SlowsAVnodalconducVon.AlsodecreasesSVRandincreasescoronarybloodflow
Indica6on:
-Tachydysrhythmias,includingsupra-andventriculartachycardias,atrialflu~erandatrialfibrillaVon,andthoseassociatedwithWPWsyndrome
DoseRange:
-Loadingdose:IV5mg/kg(usually300mg)over1hour,followedby900mgover23hours
-Maintenance:IV300-600mg/day(inareducingdose),andconsiderswitchingtooral/ngformulaVonwhenappropriate
Presenta6on/compa6bility:
-150mgor400mgvial/ONLYCOMPATIBLEwith5%DEXTROSE
-IVLoadingdose:makeup5,g/kg(300mg)in100-250ml5%dextrose(Consider100mldiluentforCVCadministraVon,
---------� 115
whereasuse250mldiluentforperipheraladministraVonvialargeborecannula),thenmakeup900mgin500mls5%dextrose
Notes:
Useadedicatedline,shouldbegivencentrally.
Peripheraluse–usealarge-borecannula,andavoidlongtermadminperipherally.Risksofhypotensionandbradycardia,photosensiVvity,GIupset,andlongterm,cornealmicrodeposits,hypothyroidism,pneumoniVsorlungfibrosis,andcirrhosis
Renalimpairment/CVVH:
-GFR<10DoseasinnormalrenalfuncVon
CVVHDF:Notdialysed.DoseasinnormalrenalfuncVon
---------� 116
Apro?nin:
DoseRange:
-TestDose10,000units(1mL)
-LoadDose2millionunits(x4syringes)
-Pumpdose2millionunits
-Infusion½millionunits/hr(50mL/hr)
-TOTDose=7millionunits(max14amps)
---------� 117
Atenolol
Introduc6on:
-Cardio-specificbeta-blocker(Beta1)
-CausesreducVonininotropy,leadingtoafallinO2consumpVon
AnVhypertensiveandanVdysrhythmicproperVes
Indica6on:
-Angina,hypertension,tachydysrhythmiasinacutephaseofMIandprevenVonofre-infarcVon
DoseRange:
-IVBolus:1-2.5mg(maxrate1mg/min),repeatedat5minintervalstoamax10mgtotal
IVinfusion:150mcg/kgover20mins,12hourly
BewareIV/POdosesvarybyafactorof10.
---------� 118
Notes:
Sideeffectsincludebronchospasm,bradycardia,heartfailuredeterioraVon,posturalhypotension.
Contra-indica6ons:
SecondorThirddegreeheartblockorsicksinussyndrome
Uncontrolledheartfailure/Cardiogenicshock
CauVoninCOPD/Asthma
Reducedoseinrenalfailure
Renalimpairment/CVVH:
-GFR<10:DoseasinnormalrenalfuncVon
-CVVHDF:Dialysed.DoseasinnormalrenalfuncVon
---------� 119
Atropine:
Introduc6on:
-AnVcholinergic/anVmuscarinic
-BlocksvagalacVvityleadingtoarelaVvetachycardia
Indica6on:
-Counterbradycardia
DoseRange:
-IV/IM600mcg
Presenta6on:
-600mcgvial
---------� 120
-1mgminijetsavailable
Notes:
PainfulonIMinjecVon
Causesdrymouth,andreducedsalivary,bronchialsecreVons,andsweaVng
---------� 121
Calcium Gluconate:
Introduc6on:
-EssenValforintracellularmuscleandnervefuncVon,includingcardiomyocytecontracVon
-CoagulaVonfactorIV–EssenValco-componentofClo�ngcascade
Indica6on:
-Hypo-calcaemia.AimionisedCa2+(onbloodgas)>1.15
-ToincreaseheartcontracVlityandvascularsmoothmuscletone
-Asacardiacmyocytemembranestabiliserinhyperkalaemia
DoseRange:
-SlowIVbolus10-20mls(atmaxrateof2mlsof10%(0.44mmol)permin)
Presenta6on:
---------� 122
-10mlampuleof10%Calciumgluconate,containing2.2mmolin10mls
-CompaVblewith0.9%Salineand5%dextrosesoluVons
Notes:
Cancause:
nausea/vomiVng/flushing/
vasomotorcollapse/hypotension/tachycardias
CauVoninpaVentswithhyperphosphataemia
Renalimpairment/CVVH:
-GFR<10:DoseasinnormalrenalfuncVon.Titratetoresponse
-CVVHDF:Dialysed.DoseasinnormalrenalfuncVon
---------� 123
Digoxin: Introduc6on:
-AnanVdysrhythmicdrugthatslowsAVnodalconducVon,therebyslowingventricularresponsetoAF.AposiVveinotrope.AlsodepressesSAnodedischarge
Indica6on:
-AtrialfibrillaVonoratrialflu~er/ChronicCCF/PrevenVonofsupraventriculardysrhythmiasfollowingthoracotomy
DoseRange:
-Loadingdose:500-1000mcgin24h
-Maintenancedose:62.5-250mcgodaccordingtolevels
IV/POswitch:Note100mcgIV=125mcgoral
Presenta6on:
-CompaVblewith0.9%NaCland5%dextrose.Dilutein50-100mldiluent(Maxconc.50mcg/ml)
Notes:
SEincludevasoconstricVon,hypertensionanddecreasedcoronarybloodflowwithrapidinjecVon,Anorexia,N&V,diarrhoea,headache,drowsiness,Dysrhythmias,2Oand3oAV
---------� 124
block,Ectopics,atrialorventriculardysrhythmiasindicateoverdose,Ventricularbi-ortri-geminy.Conatraindicatedin2Oor3oAVblock
Monitoring:
Checklevel6hpostdose.-Aim0.9-2.6micromol/litre
MonitorPotassium:HypokalaemiasensiVsesthemyocardiumtodigoxin.ThereforeAimk>4
Renalimpairment/CVVH:
-GFR20-50:125-250mcg/day.10-20:125-250mcg/dayandmonitorlevelsclosely.<10:62.5mcgdailyoralternatedaysandmonitorlevelsclosely.Notdialysed.DoseasinGFR10-20.
Dopamine:
Introduc6on:
-Anoradrenalineandadrenalineprecursor
-Hasdirectdopaminergicagonisteffects,withaddiVonalbeta-adrenergicandalphaadrenergicagonismwithincreasingconcentraVonrespecVvely.
---------� 125
Indica6on:
-Toincreaserenal(andmesenteric)bloodflow
-Forinotropyinlowcardiacoutputstates
DoseRange:
1-3mcg/kg/min:DAagonistincreasesrenalbloodflow
3-10mcg/kg/minaddiVonalBetaagonism inotropicandchronotropy
>10mcg/kg/minaddiVonalalphaagonism increasesSVR,PVR
Presenta6on:
-200mgin5mlvial
-CompaVblewith0.9%sodiumchlorideand5%dextrose
-Drawup200mgin50mls.
Rate1-10ml/h
Notes:
-Riskofarrhythmiasathigherdoses
---------� 126
-AlphamediatedvasoconstricVonoutweighsdopaminergicrenalvasodilaVonathighdoses
Renalimpairment/CVVH:
-GFR<10DoseasinnormalrenalfuncVon.
-CVVHDF:Notdialysed.DoseasinnormalrenalfuncVon
---------� 127
Ephedrine:
Introduc6on:
-PosiVveinotrope
-AlphaagonistleadingtovasoconstricVon
Indica6on:
-Hypotensionunderanaesthesia
DoseRange:
-3-6mgevery3-4mins.Max30mg
Presenta6on:
-CompaVblewith0.9%salineand5%dextrose
---------� 128
Notes:
Sideeffectsincludeheadache,tremor,dysrhythmias,N&V
---------� 129
Esmolol:
Introduc6on:
-ArelaVvelycardiospecificbetablockerwithveryshortduraVonofacVon(Half-life9mins).
Indica6on:
-Shorttermtreatmentofsupra-ventriculartachycardias
-PerioperaVvehypertensionortachycardia
DoseRange:
-Usually50-200mcg/kg/minadequate
-Aloadingdoseof500mcg/kg/minfor1min,followedbyamaintenancedoseof50-200mcg/kg/minisreasonableforSVTorimmediatecontrolofperioperaVvetachycardiaandhypertension
Presenta6on:
-10mlvialcontaining100mg(10mg/ml)
-Pre-madebagsof2500mgin250mls(10mg/ml)
-InjecVonconcentrate250mgin1ml–alwaysdiluteinto250mls0.9%NaClor5%dextrosetomakeaconcentraVonof10mg/ml)
---------� 130
Notes:
-Cancausebradycardia,dizziness,heartfailure,andvenousirritaVonorthrombophlebiVs.Thereforegivecentrallyorviaalarge-borecannula.
-Contraindicatedinhypotensionandbradycardia,2Oand3oheartblock,sicksinussyndrome.
-CauVoninasthmaandseverePVD.
-80%HepaVcallycleared.ThereforedoseasnormalinRF.
Renalimpairment/CVVH:
-GFR<10DoseasinnormalrenalfuncVon.
-CVVHDF:Unknowndialysability.DoseasinnormalrenalfuncVon
---------� 131
GTN:
Introduc6on:
-VasodilaVonofarteriesandveins
Indica6on:
-Hypertension
-Unstableangina
DoseRange:
-10-100mcg/min
Presenta6on:
-Comesas50mgin50mlsNeat
-Rate1-10ml/h.Tachyphylaxisoccursin8-24h
Notes:
---------� 132
Sideeffectsincludehypotensionandpossiblereflextachycardia,N&Vandheadaches.
CancausevenVlaVon/perfusionmismatchleadingtoincreasedright-to-lecshuntandreducedoxygensaturaVons(duetouncouplingofhypoxicpulmonaryvasoconstricVon)
Contraindicatedinseverehaemorrhage,uncorrectedhypovolaemia,severehypotension
Renalimpairment/CVVH:
-GFR<10DoseasinnormalrenalfuncVon.
-CVVHDF:Notdialysed.DoseasinnormalrenalfuncVon
---------� 133
Isoprenaline:
Introduc6on:
-Beta1andBeta2agonistproducinginotropyandchronotropy.Thebeta2acVvityalsocausesvasodilataVonandbronchodilaVon.
Indica6on:
-Chronotropyforbradycardiarefractorytoatropine
-Forthetreatmentofcompleteheartblock
DoseRange(Bridgetopacing):
-0.05-0.5mcg/kg/min
Presenta6on:
-1mgin10mlampuleor2.25mgin2mlampule
-CompaVblein0.9%salineand5%glucose
---------� 134
-Makeup4.5mgin50mls.
-Runat1-10ml/h
Notes:
-Cancausehypoxiaanddecreasedrenalbloodflow,hyperglycaemia,palpitaVons,angina,dysrhythmias,hypotension.
EPexperience:
200mcg(=1vial)makeupto50mLsaline
Conc=4mcg/mL
Run50mL/hr->100->150->300mL/houraccordingtoelectrophysiologist
Levosimendan:
Introduc6on:
-AcardiacmuscleCalciumsensiVzer.
-WorksindependentlyofcAMPandthereforeshouldnotinteractwithbetaagonistsorphospodiesteraseinhibitors
---------� 135
Indica6on:
-Acuteheartfailure,usuallywhenrefractorytootheragents
DoseRange:
-0.1mcg/kg/min+/-loadingdose3-24mcg/kgover10mins(3pracVcal->upto6)
-Cangodownto0.05orupto0.2mcg/kg/minmax
Presenta6on:
-2.5mg/mLin10mLvials
-Addx1vialto250mLdextrose5%
-Finalconc=50mcg/mL
---------� 136
Lidocaine infusion:
Introduc6on:
-ClassIanVdysrhythmic(Na+channelblocker)
Indica6on:
-Arrhythmia
DoseRange:
-Bolus/loadingdose50-100mgIV
-4mg/minfor30mins(60ml/h)
-2mg/minfor2hrs(30mL/hr)
-1mg/minfor24hrs(15mL/hr)
-Max200-300mg/hr
---------� 137
Presenta6on:
-2000mgin500mLglucose5%
=4mg/mLconcentraVon
Notes:
- ContraindicatedinPorphyria
Renalimpairment/CVVH:
-GFR<10DoseasinnormalrenalfuncVon.
-CVVHDF:Notdialysed.DoseasinnormalrenalfuncVon
---------� 138
Methylene Blue:
Introduc6on:
-MethyleneBluecanincreaseSVRbyinhibiVngtheacVvaVonofsolubleguanylatecyclaseandtherebyblockingthesynthesisofthepotentvasodilator,nitricoxide.
Indica6on:
-CanbeusedtoincreaseSVRthatisrefractorytonoradrenalineandothervasopressors.
DoseRange:
-1-2mg/kgboluswith1-2mg/kg/hrinfusion
-SmalleramountsmayhavedramaVcclinicaleffect
Presenta6on:
-Availableas1%w/vsoluVon(10mg/ml).
---------� 139
-Diluteintoasuitablevolumeof0.9%salineor4%glucose0.18%saline.
Notes:
-Contraindicatedinglucose-6-phosphatedehydrogenasedeficiency.
-CauVoninsevererenalfailureduetoaccumulaVon
-Donotmixwithotherdrugs
-WillcausediscolouraVonofskinandurine.
-CancausehaemolyVcanaemia,andmethaemoglobinaemiaacerprolonged/highdoseuse,reducVoninplateletcount,andVssuedamageifextravasaVonoccurs.
---------� 140
Milrinone:
Introduc6on:
-AphosphodiesteraseIIIisoenzymeinhibitorofcardiacandvascularmuscle
-ProducesposiVveinotropyandvasodilataVon-Alsocauseslusitropyanddromotropywithli~leornoincreaseinchronotropy.
Indica6on:
-Lowcardiacoutput,parVcularlyinthese�ngofincreasedLVEDP,pulmonaryhypertensionorRVfailure
-Asanadjuncttobetaagonists
DoseRange:
-0.375-0.75mcg/kg/min
---------� 141
Presenta6on:
-Availableas10mgin10mls.
-CompaVblewith0.9%salineand5%glucose
-Drawup10mgofdruginto50mlsdiluent.
-Rate5-10ml/h
Notes:
-Renallycleared.Thereforereducedoseinrenalfailure.
-4hhalflife
---------� 142
Noradrenaline:
Introduc6on:
-Beta1andalphaagonist.CausesincreasedSVRwhilstalsomaintainingcardiacoutput.
Indica6on:
-Refractoryhypertensionsecondarytovasoplegia
-ModulaVonofvasodilaVngdrugs
DoseRange:
-0.01-0.5mcg/kg/min
Presenta6on:
-UsualdiluVonis4mgin50mlsor8mgin100mls.
-CompaVblewith0.9%NaCland5%glucose.
---------� 143
-Runat0-10ml/h.
-ConcentraVonsmaybedoubledorquadrupled
Notes:
-Cancauseperipheralischaemia,reducedrenal-bloodflowathighdoses,andhyperglycaemia
Phentolamine:
Introduc6on:
-Alphaantagonist,leadingtoadecreaseinSVR
Indica6on:
-Acutehypertension
DoseRange:
---------� 144
-IVBolus:2-5mg,repeatedasrequired
Notes:
-Cancausereflextachycardiaanddysrhythmias,diarrhoea,nauseaandvomiVng,increasesgastricacidsecreVon.
-ContraindicatedinmyocardialinfarcVonandhypotension.
---------� 145
Phenylephrine:
Introduc6on:
-Alphaagonist,leadingtoariseinSVR.
Indica6on:
-Hypotensionsecondarytovasoplegia
DoseRange:
-IVbolus:100mcgrepeatedasrequired
-IVinfusion:30-180mcg/minVtratedaccordingtoresponse
Presenta6on:
-1mgin10mls(100mcg/ml)
---------� 146
-Beware10mgin1ml(strongphenylephrine)available.RequiresdiluVon.
CommondiluVons:
-10mgin100ml0.9%NaClbag(100mcg/ml)
-10mgdilutedto10mls0.9%Nacl(1mg/ml)foruseonlyinCPBcircuitbyperfusionist
Notes:
-Causesreflexbradycardia,hypertension,dysrhythmias,nauseaandvomiVng,sweaVng,increasedsalivaVon,urinaryretenVon.
-Contraindicatedinhypertensivestates.CauVonwithhyperthyroidism.
---------� 147
Sodium Nitroprusside (SNP):
Introduc6on:
-Potentarterialandvenousvasodilator,reducingSVR.
-CausescerebralvasodilaVon
Indica6on:
-Severehypertension
-Acuteheartfailure
DoseRange:
-Hypertension:0.5-8mcg/kg/min
Presenta6on:
-Makeup50mgin50mls
-CompaVblewith0.9%NaCland5%glucose
---------� 148
-Runat2-20ml/h
Notes:
Cancausescyanidetoxicity,tachycardia,dysrhythmiasandmetabolicacidosis.
AnVdoteforcyanidetoxicityissodiumthiosulphate(onCTITU,ED,andpharmacy)
---------� 149
Vasopressin:
Introduc6on:
-ActonV1areceptorsonsmoothmuscletoproducevasoconstricVon.
Indica6on:
-RefractoryhypotensionsecondarytolowSVR
DoseRange:
-CompaVblewith5%dextrose.
-DONOTMIXwithotherinotropes
-Makeup40unitsin40mls.
-Runat2-3units/h
Notes:
---------� 150
CausespulmonaryvasodilaVon,increasedcorVsol,diuresisatlowdoses,plateletaggregaVonathighdoses.
Ch. 7 – Notes
---------� 151
---------� 152